[144] Lexeo Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Lexeo Therapeutics (LXEO) filing Form 144 to notify a proposed sale of 1,115 common shares through Fidelity Brokerage Services on 08/18/2025. The shares were acquired on 08/15/2025 upon restricted stock vesting from the issuer and the consideration is listed as compensation. The filing reports an aggregate market value of $5,205.04 for the shares and shows 54,001,214 shares outstanding, indicating the sale represents a very small fraction of the outstanding common stock. The filer certifies under the form that they are not aware of undisclosed material adverse information about the issuer.

Positive

• Disclosure compliance: Form 144 is filed with required details, indicating adherence to Rule 144 notification procedures
• Securities origin specified: Shares were acquired via restricted stock vesting and payment is listed as compensation, clarifying the source
• Immaterial size: 1,115 shares with aggregate value $5,205.04 versus 54,001,214 outstanding shares, indicating negligible dilution/market impact

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice for vested restricted shares; appears procedural and compliant.

The filing documents a standard Rule 144 notice where restricted stock vested and the holder intends to sell 1,115 shares via a broker on a specified date. Required fields are completed: acquisition date, nature of acquisition (restricted stock vesting), payment nature (compensation), broker identity, proposed sale date, and aggregate market value. There is no reportable sale in the prior three months, and the filer affirms absence of undisclosed material adverse information. From a compliance perspective, this is a routine disclosure consistent with Rule 144 procedural requirements.

Equity Risk Analyst

TL;DR: Transaction size is immaterial relative to outstanding shares; limited investor impact.

The notice shows the shares originated from issuer compensation and are to be sold through an established broker on NASDAQ. The aggregate value is $5,205.04 against 54,001,214 shares outstanding, making this sale immaterial to supply or market liquidity. No prior sales in the past three months are reported for the account. There is no disclosure in the filing of any adverse operational or financial developments.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1115	5205.04	54001214	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Vesting	Issuer			1115	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Lexeo Therapeutics' Form 144 (LXEO) report?

The Form 144 notifies a proposed sale of 1,115 common shares acquired on 08/15/2025 via restricted stock vesting, with a proposed sale date of 08/18/2025 through Fidelity.

How much are the shares worth in the LXEO Form 144 notice?

The filing lists an aggregate market value of $5,205.04 for the 1,115 shares to be sold.

Does the LXEO Form 144 show prior sales by the filer in the last three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

What portion of Lexeo's outstanding stock does this sale represent?

The filing reports 54,001,214 shares outstanding; the 1,115-share sale is a very small fraction of that total.

Who is the broker handling the sale in the LXEO Form 144?

The broker listed is Fidelity Brokerage Services LLC with the sale to occur on NASDAQ.